Century Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Die Gewinne von Century Therapeutics werden voraussichtlich zurückgehen um 7.6% pro Jahr. Der Gewinn je Aktie wird voraussichtlich um 16.5% pro Jahr steigen.

Wichtige Informationen

-7.6%

Wachstumsrate der Gewinne

16.51%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.2%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	19 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Dec 17

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. ( NASDAQ:IPSC ) shareholders have had their patience rewarded with a 32% share price jump in...

Analyseartikel • Nov 30

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyseartikel • Oct 08

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Century Therapeutics, Inc.'s ( NASDAQ:IPSC ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong...

Seeking Alpha • Jun 20

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Summary Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses. Read the full article on Seeking Alpha

Analyseartikel • Mar 06

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Feb 01

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Summary Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions. Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a complete clinical response. However, Century Therapeutics has a limited cash position and needs to prove the efficacy of their therapies before being considered a confident investment. Read the full article on Seeking Alpha

Analyseartikel • Oct 23

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Aug 25

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Century Therapeutics (NASDAQ:IPSC) will begin a phase 1 study of its allogeneic cell therapy CNTY-101 by the end of the year after receiving Investigational New Drug clearance from the US FDA. CNTY-101 is under investigation for relapsed or refractory CD19 positive B-cell malignancies. In the ELiPSE-1 study, all patients will receive an initial standard dose of conditioning chemotherapy. Schedule A consists of a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101. CNTY-101 is derived from a clonal induced pluripotent stem cell (iPSC) master cell bank that yields homogeneous product. Seeking Alpha's Quant Rating views Century (IPSC) as a hold with strong grades for profitability and momentum.

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:IPSC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	N/A	-120	-158	N/A	2
12/31/2027	N/A	-107	-145	N/A	4
12/31/2026	N/A	-93	-138	N/A	4
3/31/2026	N/A	-108	-95	-95	N/A
12/31/2025	109	-10	-105	-104	N/A
9/30/2025	113	-26	-113	-112	N/A
6/30/2025	114	-23	-115	-115	N/A
3/31/2025	115	-22	-115	-115	N/A
12/31/2024	7	-127	-110	-110	N/A
9/30/2024	3	-130	-113	-112	N/A
6/30/2024	2	-131	-103	-97	N/A
3/31/2024	1	-133	-99	-89	N/A
12/31/2023	2	-137	-102	-88	N/A
9/30/2023	2	-129	-104	-85	N/A
6/30/2023	5	-127	-121	-96	N/A
3/31/2023	6	-125	-133	-102	N/A
12/31/2022	5	-131	-17	14	N/A
9/30/2022	5	-127	-28	13	N/A
6/30/2022	2	-123	-34	13	N/A
3/31/2022	1	-115	-27	20	N/A
12/31/2021	N/A	-96	-134	-89	N/A
9/30/2021	N/A	-83	-108	-78	N/A
6/30/2021	N/A	-70	-82	-63	N/A
3/31/2021	N/A	-62	-66	-57	N/A
12/31/2020	N/A	-54	-51	-41	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IPSC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IPSC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IPSC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von IPSC schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: IPSC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IPSC in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/24 04:31
Aktienkurs zum Tagesende	2026/05/22 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Century Therapeutics, Inc. wird von 9 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Geoffrey Meacham	BofA Global Research
Chen Yang	BofA Global Research
William Maughan	Canaccord Genuity

Century Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 22% to US$3.67

Price target decreased by 11% to US$4.25

Consensus revenue estimates increase by 115%

Price target decreased by 8.3% to US$4.40

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 2,092%

Recent updates

New major risk - Financial position

Price target increased by 22% to US$3.67

Century Therapeutics, Inc., Annual General Meeting, Jun 11, 2026

Full year 2025 earnings: EPS exceeds analyst expectations

Century Therapeutics, Inc. announced that it has received $134.997458 million in funding from a group of investors

New major risk - Shareholder dilution

Century Therapeutics, Inc. Announces Resignation of Carlo Rizzuto as Director., Effective December 18, 2025

New minor risk - Share price stability

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. Announces Board and Committee Appointments

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.37 loss in 3Q 2024)

Century Therapeutics, Inc. Announces New Beta Islet Program for Type 1 Diabetes

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Price target decreased by 11% to US$4.25

Nasdaq Grants Century Therapeutics an Additional 180 Calendar Day Period, or Until February 23, 2026, to Regain Compliance with the Bid Price Rule

Century Therapeutics, Inc. Announces Board and Committee Changes, Effective August 14, 2025

Century Therapeutics, Inc. Announces Departure of Morgan Conn, Ph.D. as the Chief Financial Officer, Effective July 11, 2025

Consensus revenue estimates increase by 115%

Price target decreased by 8.3% to US$4.40

New major risk - Financial position

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 2,092%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Century Therapeutics, Inc. Provides Business Update for Clinical Pipeline for CNTY-101

Century Therapeutics Receives A Notification Letter from the Nasdaq Stock Market Regarding Listing Rule 5450(a)(1)

Price target increased by 8.0% to US$9.00

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-Derived iNK Cell Therapy Cnty-101 in B-Cell Mediated Autoimmune Diseases

New major risk - Shareholder dilution

New minor risk - Market cap size

Consensus revenue estimates increase by 23%

Price target decreased by 11% to US$10.40

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Century Therapeutics, Inc. Appoints Chad Cowan as Chief Scientific Officer, Effective October 1, 2024

Century Therapeutics, Inc. Appoints Morgan Conn as Chief Financial Officer, Effective October 14, 2024

Price target decreased by 7.1% to US$11.33

Consensus revenue estimates increase by 24%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting

Price target decreased by 18% to US$12.20

Consensus revenue estimates increase by 77%

Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.53 loss in 1Q 2023)

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations